Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene
- 512 Downloads
The study was supported by grants from Associazione Italiana per la Ricerca sul Cancro (AIRC) (Special Program “Molecular Clinical Oncology 5 per mille” AGIMM-AIRC Gruppo Italiano Malattie Mieloproliferative- project no. 1005 to MC, and my first AIRC grant MFAG project 15672 to ER) and by a grant form Italian Ministry of Health (GR-2010-2312855) to ER. A special thank to Dr. Laura Tassi and Prof. Giorgio Lo Russo for their technical support.
Conflict of interest
The authors do not have potential conflicts of interest related to this paper.
- 1.Schwaab J, Knut M, Haferlach C, Metzgeroth G, Horny HP, Chase A, Tapper W, Score J, Waghorn K, Naumann N, Jawhar M, Fabarius A, Hofmann WK, Cross NC, Reiter A (2015) Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes. Ann Hematol 94(2):233–8CrossRefPubMedGoogle Scholar